Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) exert neuroprotective effects in neurodegenerative diseases (Alzheimer's, Parkinson's, Multiple Sclerosis) by modulating synaptic plasticity, reducing neuroinflammation, and promoting neurogenesis, although clinical trial outcomes remain variable.

GLP-1 drugs like semaglutide and liraglutide show promise in protecting brain cells and slowing cognitive/motor decline in diseases like Alzheimer's and Parkinson's, based on strong lab studies. However, human trials have been mixed, likely due to how patients are chosen and how trials are run. If you have a neurodegenerative condition, discuss with your doctor whether the potential brain benefits outweigh the risk of stomach side effects, especially if you are frail or elderly.

Novel GLP-1 receptor agonists (e.g., NLY01, tirzepatide) are being developed to enhance central nervous system penetration and efficacy, with some showing specific benefits in younger patient subgroups.

Newer GLP-1 drugs like NLY01 and tirzepatide are being designed to work better in the brain. Early results suggest they might help younger patients more than older ones. If you are interested in these treatments, ask your doctor about the latest clinical trials and whether a newer agent might be suitable for your specific condition and age.

Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a statistically significant increase in the dispensing of antidepressants, suggesting a potential adverse effect on mood or mental health.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Trulicity), be aware that there is a statistically higher chance you might be prescribed an antidepressant. This does not mean everyone will experience mood issues, but it is a known risk signal. Monitor your mental health closely, especially if you have a history of depression, and discuss any mood changes with your doctor immediately.

AMPK activation suppresses leptin secretion in adipocytes independently of adipogenesis and adipocyte maturity, challenging the view that AMPK's primary benefit is promoting adipose expansion.

While exercise and certain drugs activate AMPK to help store fat healthily, this research highlights that AMPK also directly reduces leptin, a hormone that tells your brain you're full. In obesity, high leptin levels cause resistance. By suppressing leptin secretion, AMPK activation might help restore the body's natural ability to feel full, offering a pathway to treat leptin resistance without just focusing on fat storage.

Semaglutide is associated with a statistically significant signal of disproportionate reporting for depressive disorders in real-world pharmacovigilance data, whereas liraglutide and tirzepatide show no such signal.

If you are taking semaglutide, be aware that real-world data shows a higher reporting rate of depression compared to other GLP-1RAs like liraglutide or tirzepatide. This does not mean the drug definitely causes depression, but it suggests you should monitor your mood, especially if you are female. Discuss any mood changes with your doctor, as they may consider drug-specific monitoring.

Long-term use of GLP-1 receptor agonists (specifically liraglutide, dulaglutide, and exenatide) is associated with an increased risk of thyroid tumors, including C-cell hyperplasia and medullary thyroid carcinoma, primarily through the stimulation of GLP-1 receptors on thyroid C cells leading to calcitonin gene expression and cellular hyperplasia.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Victoza), your doctor should monitor your thyroid health, specifically checking calcitonin levels and potentially performing ultrasounds if you have symptoms or risk factors. This is because these drugs stimulate thyroid C-cells, which can lead to hyperplasia in animal models. While human risk is debated, caution is advised, especially if you have a family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 (MEN2).

GLP-1 receptor agonists may increase the risk of acute pancreatitis and pancreatic cancer, although meta-analyses have sometimes excluded this risk, and the evidence remains inconclusive with conflicting study results.

Be aware of symptoms of pancreatitis (severe abdominal pain, nausea, vomiting) while on GLP-1 medications. While the absolute risk is debated, it is a known potential side effect. Report any persistent abdominal pain to your doctor immediately.

GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide) are associated with statistically significant signals for otolaryngologic adverse events, specifically GERD, Medullary Thyroid Carcinoma (MTC), and Papillary Thyroid Carcinoma (PTC), across all approved drugs.

If you take a GLP-1 drug like Ozempic or Wegovy, be aware that reports of acid reflux (GERD) and thyroid issues (MTC/PTC) are significantly higher than background noise in the FDA database. You should discuss these risks with your doctor and monitor for symptoms like persistent heartburn or neck lumps, but do not stop medication without medical advice.

Semaglutide and Liraglutide show significant signals for specific otolaryngologic adverse events including anosmia, dysgeusia, Bell's palsy, and tinnitus, which are not as strongly or consistently reported with other GLP-1 RAs.

If you take Semaglutide or Liraglutide and experience loss of smell, taste changes, ringing in the ears, or facial weakness (Bell's palsy), these are reported side effects. Inform your healthcare provider, as these may require management adjustments.

Dietary supplementation with omega-3 polyunsaturated fatty acids (specifically DHA) attenuates nonalcoholic steatohepatitis (NASH) and fibrosis by suppressing betacellulin (BTC) expression, thereby inhibiting hepatic stellate cell proliferation and collagen production.

To support liver health and potentially reduce fibrosis risk, prioritize dietary sources of Docosahexaenoic Acid (DHA), a type of Omega-3 fatty acid. Research suggests DHA is particularly effective at suppressing betacellulin, a protein that drives liver scarring. While general Omega-3s help, DHA appears to have a stronger specific effect on this pathway. Consult a healthcare provider before making significant dietary changes, especially if you have existing liver conditions.

Dual activation of GPR10 and NPFF2 receptors by lipidated PrRP31 metabolites produces robust, long-acting weight loss in diet-induced obese mice, whereas GPR10-selective activation does not.

This research suggests that for obesity treatment, targeting both GPR10 and NPFF2 receptors simultaneously may be more effective than targeting GPR10 alone. The study used lipidated peptides in mice, showing significant weight loss. This is preclinical data and not a direct human treatment recommendation yet.

Obstructive Sleep Apnea (OSA) is an independent risk factor for the development of Type 2 Diabetes (T2DM) and MASLD, primarily through mechanisms of intermittent hypoxia, sympathetic hyperactivity, and inflammation, rather than solely through obesity.

Treating sleep apnea is not just about feeling rested; it is a critical step in preventing diabetes and liver disease. The lack of oxygen during sleep triggers stress hormones and inflammation that damage metabolism.

Pioglitazone administration reverses hyperglycemia and restores beta-cell maturity markers (increased insulin/Nkx6.1, decreased Aldh1a3) in diabetic db/db mice, while promoting a 'browning' gene expression profile (UCP-1, Cidea) in white adipose tissue.

Pioglitazone effectively lowers blood glucose and improves beta-cell function in insulin-resistant individuals, even if it causes some weight gain. This gain is largely subcutaneous and correlates with improved metabolic health. It also promotes 'browning' markers in fat tissue, suggesting enhanced metabolic flexibility.

Chronic administration of the dual beta-2/beta-3 adrenergic agonist ATR-127 significantly reduces body weight and fat mass while improving glucose homeostasis in diet-induced obese mice, without causing cardiac hypertrophy.

This research suggests that a specific drug targeting fat and muscle metabolism (ATR-127) can reduce body fat and improve blood sugar control in obese individuals without harming the heart, a common side effect of older weight-loss drugs. This is currently only proven in mice and lab cells, so it is not yet available for human use.

Post-exercise cold water immersion (CWI) attenuates resistance training-induced muscle hypertrophy compared to resistance training alone.

If your main goal is building maximum muscle size, avoid cold water immersion immediately after your resistance training sessions. The evidence suggests that cooling the muscles right after lifting blunts the biological signals (like protein synthesis and mTOR signaling) required for growth. If you must use CWI for recovery, schedule it at least several hours away from your training or on rest days to minimize interference with hypertrophy.

Targeting specific protein posttranslational modifications (PTMs) such as phosphorylation, ubiquitination, and acetylation offers therapeutic potential for metabolic diseases including diabetes, obesity, and NAFLD by modulating insulin signaling, glucose metabolism, and inflammatory pathways.

This paper suggests that future treatments for metabolic diseases may target specific molecular switches (PTMs) in your cells. While you cannot directly 'dose' these switches, understanding them explains why current drugs (like SGLT-2 inhibitors or GLP-1 agonists) are effective and why lifestyle changes (diet/exercise) that influence these pathways (e.g., AMPK activation) are beneficial. Consult a doctor about emerging therapies targeting these pathways.

Use of GLP-1 receptor agonists (semaglutide and tirzepatide) is associated with an increased risk of alopecia, potentially mediated by rapid weight loss-induced telogen effluvium or direct receptor interaction in hair follicles.

If you are taking semaglutide or tirzepatide and notice increased hair shedding, do not panic. This is likely telogen effluvium caused by rapid weight loss or metabolic stress, which is usually reversible. Ensure you are eating enough protein and nutrients. Talk to your doctor; they may adjust your plan or provide reassurance, but stopping the medication abruptly is rarely necessary unless the shedding is severe.

The presence of satellite cells reduces ex vivo skeletal muscle force production specifically during the morning, whereas this effect is absent in the afternoon.

If you are training for maximum force output, be aware that your muscles may naturally produce less force in the morning due to circadian regulation. This is not a sign of weakness, but a biological rhythm. If possible, schedule heavy strength training in the afternoon when this circadian suppression is absent.

The reduced force production in the morning associated with satellite cells results in significantly less contractile injury (force loss and dystrophin-negative fibers) following eccentric exercise.

Eccentric exercise causes damage, but the extent of damage varies by time of day. Morning training with satellite cells present may result in less structural damage (dystrophin loss) than afternoon training, potentially due to lower force generation. This suggests morning might be a safer time for high-intensity eccentric work if injury prevention is the goal.

The reduced force production in the morning is mechanistically linked to lower calcium availability for contractile units, as indicated by reduced caffeine-induced contracture force.

This is a basic science finding. It suggests that the reason morning muscles might be weaker is not just neural, but involves how much calcium is available to trigger contraction. This is not directly actionable for training but informs future research on timing.

GLP-1 receptor agonists do not exacerbate psychotic symptoms in schizophrenia and provide metabolic benefits, but have not demonstrated consistent effects on core psychiatric symptomatology.

For people with schizophrenia, GLP-1 medications are safe and help with weight gain caused by antipsychotics, but they do not treat the psychosis itself. Do not expect them to improve hallucinations or cognitive function. They are a tool for metabolic health, not psychiatric symptom management in this population.

Tirzepatide significantly reduces urine albumin-to-creatinine ratio (UACR) compared to placebo and insulin, indicating improved renal microvascular health, while maintaining a neutral effect on estimated glomerular filtration rate (eGFR) over short-term follow-up.

If you have Type 2 Diabetes or obesity, Tirzepatide (5-15 mg weekly) significantly lowers albuminuria (a marker of kidney stress) compared to placebo or insulin, without negatively impacting your kidney's filtration rate over 6-18 months. This suggests renal protection, particularly for those with existing high albuminuria. However, long-term data is still needed.

Combining GIPR agonism or antagonism with GLP-1 R agonism produces synergistic weight loss in preclinical models, whereas GIPR signaling is not required for this synergy in humans.

Combining GIP and GLP-1 hormones (as seen in drugs like tirzepatide) is more effective for weight loss than GLP-1 alone, likely because they work together synergistically. However, the exact way this works in humans is still debated, as animal studies do not perfectly predict human biology.

GIPR antagonism reduces body weight in preclinical models by restoring leptin sensitivity, thereby reducing appetite.

Blocking GIP receptors can help obese individuals lose weight by making their bodies more sensitive to leptin, the hormone that signals fullness. This is currently only proven in animal models.